500 RIVER RIDGE DRIVE, NORWOOD, MA
Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
Reports Q1 2026 Financial Results and Provides a Corporate Update
Executive Appointments - Yuval Cohen and Sean Moran Employment Agreements
Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer
Annual Report to Security Holders
Investor Presentation
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload
Registration of Securities under Section 12(g)